Teleflex Unveils the UroLift Advanced Tissue Control System and the UroLift 2 System
September 09, 2021 at 06:30 am EDT
Share
Teleflex Incorporated announced that two new UroLift System products, the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System, will be launched at the American Urological Association (AUA) 2021 Annual Meeting taking place virtually September 10–13. New emerging data from the largest analysis of U.S. healthcare claims within the field of benign prostatic hyperplasia (BPH) comparing complication rates (defined as a post-operative procedure performed during a return visit to an outpatient setting) and surgical retreatment rates of BPH procedures, including the UroLift System, will also be presented. The UroLift ATC System builds on the highly successful UroLift System and features an enhanced delivery device tip designed to make it easier for urologists to treat BPH patients with a median lobe. The new UroLift 2 System is an evolution of the UroLift System platform and is engineered with innovative design features to enhance user confidence and ease of use including an ergonomic single trigger, an improved suture cutter, and simplified workflow.1 The eco-friendly Delivery Handle and implant cartridge design requires 66% less storage space, and generates nearly 50% less waste material per procedure, as compared to the prior generation UroLift System.1 Both new products support the continued utilization of the UroLift System in its full indication, which includes prostate volume <=100 cc, lateral and median lobe hyperplasia, in men 45 years of age or older.
Teleflex Incorporated specialises in the designing, manufacturing and selling of single-use medical devices for hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. Products are sold under the brand names Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck®. Net sales break down by category of products as follows:
- interventional cardiology, radiology and urology products (26.5%);
- vascular access solutions (25.9%);
- surgical devices (12.5%);
- anesthesia products (11.9%);
- other (23.2%).
Net sales are distributed geographically as follows: the United States (61.8%), Europe (25.5%), Asia-Pacific (9.1%) and other (3.6%).